Model quality check
Problem
An error spotted by the assessor triggers questions and delays access.
What I do
An independent, cell-by-cell check before submission.
Impact
Fewer avoidable technical questions.
HEOR support · Paris
Make your models HTA-ready.
Independent quality checks and country adaptations for HEOR consultancies and manufacturers, reviewed the way an HTA assessor would.
Get in touchServices
The problems I solve.
I work alongside your modellers and project leads, on the parts of a project where an outside, assessor-minded review makes the difference.
My angle: reading a model or a dossier from the HTA assessor's point of view, before the assessor does.
Country adaptation
Problem
A global model that does not follow local guidelines, for example in France or Japan.
What I do
Localise inputs and methods to the local reference case.
Impact
A model that meets local requirements without being rebuilt.
Project support
Problem
Workload peaks on long submission projects.
What I do
Hands-on help on the parts your lead assigns: inputs, scenarios, documentation.
Impact
Extra capacity without hiring, with an assessor-minded eye.
Evidence reviews
Problem
Evidence gaps that surface late in the project.
What I do
Targeted literature and real-world evidence reviews, with evidence tables.
Impact
Every input traceable to its source.
Survival data
Problem
Only published Kaplan-Meier curves are available.
What I do
Digitisation, reconstructed patient data and RMST analyses in R.
Impact
Survival inputs you can actually model with.
Reporting and slides
Problem
Model results that internal teams struggle to read.
What I do
Technical reports, summaries and clear slides.
Impact
Results your teams can present with confidence.
Also:Hospital data (PMSI)Excel and VBA toolsHTA dossier drafting supportScientific visuals and slidesAI training for access teams
Frameworks
Standards, step by step.
Each mission follows a logical path built on published references. Pick a type of work to see how they fit together, and what you receive at each step.
GoalFind the errors before the assessor does.
1
What has already been tested?
I start from the validation record of the client team, so nothing is checked twice.
Validation inventory
2
What is left to check?
I build a checklist tailored to the model, covering only what was not already tested.
Tailored checklist
3
Does every calculation hold?
I run each test, cell by cell, and record every deviation precisely.
Anomaly log
4
Is it ready to be read?
A final report structured on reporting standards, usable for HTA bodies and publications such as ISPOR.
QC report
Methodological critique on request, with the Philips checklist
GoalMake a global model fit a local agency without rebuilding it.
1
2
What changes locally?
Costs, epidemiology, care pathways, discounting: the parameters that differ by country.
Parameter map
3
Keep or replace?
An adaptation plan, element by element, from the global core model.
Adaptation plan
4
GoalShow payers what adoption will cost them, year by year.
1
Who is treated, and with what?
Eligible population, current treatment mix and expected mix after launch.
Model structure
2
3
4
GoalSupport a value argument that stands up to scrutiny.
1
What must the model represent?
Model concept and structure, agreed before any building.
Model concept
2
How to handle survival and utilities?
Recognised methods for the inputs assessors look at first.
Input methods
3
4
How well is it validated?
A clear record of what has been validated, and how.
Validation record
5
Is the report complete?
Reporting checked item by item against the standard.
Reporting checklist
Full reference list 23 references with official links
Budget impact analysis
ISPOR Budget Impact Analysis Good Practice II2014International reference for structuring a budget impact analysis: population, treatment mix, uptake, costs and scenarios.Source French HTA budget impact guideline2016Official French methods for budget impact analyses submitted to the national HTA body.Source Canadian Budget Impact Analysis GuidelinesPMPRBPractical template for budget impact analyses submitted to public drug plans in Canada.SourceCost-effectiveness and cost-utility modelling
ISPOR-SMDM Modeling Good Research Practices2012Seven-part series on how to conceptualise, build, parameterise, validate and report decision models.Source NICE DSU Technical Support DocumentsNICEOperational guidance on evidence, survival extrapolation, utilities and model structures.Source French HTA economic evaluation guideline2020Official French methods for cost-effectiveness and cost-utility analyses.Source C2H Guideline, Japan2024Official methods for cost-effectiveness evaluations submitted in Japan.Source iDSI Reference Case2016Principles for consistent economic evaluations, widely used in low and middle-income settings.SourceModel adaptation and transferability
Global Pharmacoeconomic Model Adaptation Strategies2014Recommendations and checklist for adapting a global core model to a local setting.Source ISPOR Transferability Task Force2009Framework to decide which parameters vary across countries and how far a model must be adapted.Source Welte transferability decision chart2004Knock-out criteria and checklist to judge whether results can be transferred between countries.Source Boulenger transferability checklist2005Checklist of the information needed to assess the transferability of an economic evaluation.Source EUnetHTA HTA Adaptation Toolkit2009European toolkit to assess the relevance and transferability of existing HTA material.SourceCountry guidelines: England, USA, Switzerland
NICE health technology evaluations: the manualEnglandMethods and process for NICE technology appraisals, including cost-effectiveness.Source NICE assessing resource impact process manualEnglandHow NICE estimates the budget and resource impact of its guidance.Source ICER Value Assessment FrameworkUSAMethods used by ICER to assess the value of new treatments in the US.Source AMCP Format for Formulary Submissions 5.0USADossier format for US payers, including budget impact and economic models.Source FOPH operationalisation of the WZW criteriaSwitzerlandHow the Swiss FOPH assesses efficacy, appropriateness and cost-effectiveness.Source FOPH Health Technology Assessment programmeSwitzerlandThe Swiss federal HTA programme and its published assessments.SourceQuality control and reporting
Philips checklist2006Assessment of a model's methodological quality: structure, data and consistency.Source TECH-VER2019Checklist to verify a model's technical implementation, from inputs to uncertainty analyses.Source AdViSHE2016Tool to document and assess how well a health economic model has been validated.Source CHEERS 20222022Checklist for reporting health economic evaluations clearly and completely.SourceApproach
Simple, transparent, and close to your team.
01
Scoping
A short call to understand the question, the data and the deadline.
02
Proposal
Clear scope, timeline and quote. NDA signed upfront if needed.
03
Build
Regular check-ins with your project lead and a self-check before every delivery.
04
Handover
Final files, a technical note and a walkthrough of the results.
Assessor-minded
Every model read the way an HTA reviewer will read it.
Traceable
Every finding and assumption documented and linked to its source.
Direct
One point of contact, who is also the person doing the work. French or English.
About
Mohamed Essalah Berredjem
Pharmacist and health economist, trained in HEOR within the market access team of a top 10 pharmaceutical company in France. I help HEOR consultancies and manufacturers make their models HTA-ready, through independent quality checks and country adaptations.
Industry experienceHEOR Analyst, AbbVie France
EducationPharmD, Université de Lorraine · MSc Health Economics and Market Access, Université Paris Dauphine-PSL
PreviouslyMarket research (Stethos) · Clinical research coordination (Institut de Cancérologie de Lorraine)
LanguagesFrench, English (C1)
Working together
Clear pricing.
€90 / hour
Hourly
For support on ongoing projects and ad hoc checks.
Fixed fee
Per deliverable
For a clearly scoped task, such as a model check. Quote after the scoping call.
Contact